Sensei Biotherapeutics Announces Closing of Initial Public Offering

BOSTON and ROCKVILLE, Md. , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. , a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the closing of its initial public offering of 7,000,052 shares of

Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON and ROCKVILLE, Md. , Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. , a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the pricing of its upsized initial public offering of 7,000,052

Sensei Biotherapeutics Announces Launch of Initial Public Offering

BOSTON, MA    and ROCKVILLE, MD  –  February 1, 2021  – Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has launched an underwritten initial public offering of 5,885,000

Sensei Biotherapeutics Appoints Deneen Vojta, M.D. to its Board of Directors

BOSTON, MA    and GAITHERSBURG, MD  –  January 29, 2021  – Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointment of Deneen Vojta, M.D. to its Board of Directors. Dr.

Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform

– Round co-led by Apeiron Investment Group and Catalio Capital Management – Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies BOSTON, MA  and ROCKVILLE, MD – January 11, 2021  – Sensei Biotherapeutics, Inc.,

Displaying 11 - 15 of 15